Clinical trials · Massachusetts
Lymphoma clinical trials in Massachusetts
We’re tracking 105 recruiting lymphoma studies with a site in Massachusetts — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT07014293Recruiting
Building resilience in early lymphoma survivors
This study looks at ways to help people feel stronger and cope better after finishing lymphoma treatment. If your lymphoma is under control, you may join to learn skills that improve your emotional well-being.
Boston, MassachusettsAges 18 years+ - NCT07013435Recruiting
Resilience training for lymphoma survivors
This study tests a program to help lymphoma survivors build resilience and improve long-term quality of life after treatment. It's a behavioral intervention, not a drug trial, that focuses on coping and well-being.
Boston, MassachusettsAges 18 years+ - NCT06876662RecruitingPhase 4
Continuing pirtobrutinib for CLL and lymphoma patients
This trial continues to give pirtobrutinib to people with chronic lymphocytic leukemia or certain other lymphomas who were already in a previous study with this drug. It helps researchers keep track of long-term safety and how well the drug works over time.
Boston, MassachusettsAges 18 years+ - NCT06854003RecruitingPhase 2
Study of new drug combo for untreated mantle cell lymphoma
This trial is testing a combination of chemotherapy and targeted drugs for people who have just been diagnosed with mantle cell lymphoma and haven't had any prior treatment (except short-term steroids or local radiation). It aims to see if adding newer targeted therapies can help keep the lymphoma in remission.
Boston, MassachusettsAges 18 years+ - NCT06811272RecruitingPhase 2
Epcoritamab for older or frailer adults with large B-cell lymphoma
This trial tests an outpatient treatment called epcoritamab for people with large B-cell lymphoma who are older or frail, or who have already tried one treatment. The goal is to see if this drug can help control the cancer with fewer side effects than standard therapies.
Newton, MassachusettsAges 18 years+ - NCT06742996RecruitingPhase 3
Sonrotoclax plus zanubrutinib for relapsed mantle cell lymphoma
This trial tests a new combination of two targeted therapies for people with mantle cell lymphoma that has come back or hasn't responded to prior treatment. It aims to see if adding sonrotoclax to zanubrutinib works better than zanubrutinib alone.
Boston, MassachusettsAges 18 years+ - NCT06510309RecruitingPhase 2
Rituximab plus venetoclax for untreated marginal zone lymphoma
This trial tests a combination of two drugs, rituximab and venetoclax, as a first treatment for marginal zone lymphoma that has not been treated before. The goal is to see if this drug pair is safe and effective.
Boston, MassachusettsAges 18 years+ - NCT06090539RecruitingPhase 1/Phase 2
New drug for lymphoma that has returned or not responded
This trial tests a new drug, BMS-986458, alone or with other lymphoma treatments, for people with non-Hodgkin lymphoma that has come back or not gotten better after prior treatment.
Boston, MassachusettsAges 18 years+ - NCT05800366RecruitingPhase 2
Testing glofitamab plus polatuzumab for high-risk diffuse lymphoma
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
Boston, MassachusettsAges 18 years+ - NCT05783609RecruitingPhase 2
Epcoritamab and rituximab for untreated follicular lymphoma
This phase 2 trial tests whether a combination of epcoritamab plus rituximab can work as a first treatment for follicular lymphoma. It may help people whose lymphoma is causing symptoms or affecting organs, or who have bulky disease, by targeting the lymphoma cells.
Boston, MassachusettsAges 18 years+ - NCT05010005RecruitingPhase 1
Testing ruxolitinib plus duvelisib for relapsed T-cell lymphoma
This Phase 1 study tests how safe and effective ruxolitinib plus duvelisib are in adults with certain types of mature T-cell lymphomas. You may be considered if your lymphoma has come back or worsened despite prior treatment, and the study checks whether this pill combination can help control the disease.
Boston, MassachusettsAges 18 years+ - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Boston, MassachusettsAges 1–21 - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Boston, MassachusettsAges 1–30 - NCT04669171RecruitingPhase 1/Phase 2
Vaccine treatment for slow-growing lymphoma, alone or combined
This trial tests a new vaccine medicine (EO2463) to treat indolent non-Hodgkin lymphoma (slow-growing lymphoma), either by itself or with other treatment. It may help your immune system recognize and attack lymphoma cells.
Boston, MassachusettsAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Boston, MassachusettsAges 18 years+ - NCT04045470Recruiting
Skin-device test to find drugs for T-cell lymphoma lesions
This trial tests a tiny device placed directly into skin lymphoma spots to help identify which “candidate” drugs could work. It’s mainly aimed at people with measurable skin involvement from T-cell lymphoma, after they stop certain treatments for a set time.
Boston, MassachusettsAges 18 years+ - NCT03666000RecruitingPhase 1
Azer-cel for B-cell lymphoma and leukemia that has returned
This trial tests an investigational cell therapy called Azer-cel for people with certain types of blood cancer (non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, or B-cell acute lymphoblastic leukemia) that has come back or not responded to previous treatments. The therapy uses your own immune cells that have been modified to find and attack cancer cells.
Boston, MassachusettsAges 18 years+ - NCT03328078RecruitingPhase 1/Phase 2
Emavusertib for recurrent brain lymphoma after prior treatment
This Phase 1/2 trial tests emavusertib (a targeted medicine) in adults with primary central nervous system lymphoma that has come back or not responded to treatment. It’s designed to find safe dosing and see how well the treatment can control the lymphoma in the brain/spinal fluid.
Boston, MassachusettsAges 18 years+ - NCT02332668RecruitingPhase 1/Phase 2
Pembrolizumab for children with advanced, hard-to-treat cancer
This trial tests pembrolizumab (an immunotherapy that helps the body recognize and attack cancer) in children with advanced solid tumors or lymphoma that can’t be cured. It’s designed for kids who have already tried standard treatments or don’t have standard treatment options.
Boston, MassachusettsAges 6 months–17 years - NCT01790152Recruiting
Dexrazoxane study to monitor heart damage in cancer survivors
This study tests dexrazoxane (DRZ) to see how it affects blood and heart-related “biomarkers,” or measurable signs of heart damage, after cancer treatment. It mainly targets survivors who may be at risk for cardiomyopathy (heart muscle weakness) or related heart failure.
Boston, MassachusettsAges Any age - NCT07654426RecruitingPhase 2
Heart protection during lymphoma chemotherapy
This trial tests if a heart-protecting drug (dexrazoxane) can prevent heart damage in people getting chemotherapy for certain types of large B-cell lymphoma. It is for patients who already have heart risk factors or a history of heart failure.
Boston, MassachusettsAges 18 years+ - NCT07509151RecruitingPhase 3
Surovatamig after first treatment for CLL or SLL
This trial tests a new drug called surovatamig as a follow-up treatment for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already completed their first round of therapy. The goal is to see if it helps keep the cancer from coming back.
Boston, MassachusettsAges 18–18 - NCT07231952RecruitingPhase 2
Study of pirtobrutinib, venetoclax, and rituximab for Waldenström's macroglobulinemia
This trial tests a combination of three targeted drugs for people with untreated Waldenström's macroglobulinemia (WM), a rare blood cancer. The drugs aim to shrink tumors and lower the abnormal antibody (IgM) that causes symptoms, potentially offering a new first-line treatment option.
Boston, MassachusettsAges 18 years+ - NCT07128641RecruitingPhase 2
Odronextamab for early follicular lymphoma without prior treatment
This trial tests a new immunotherapy drug, odronextamab, for people with slow-growing follicular lymphoma that hasn't been treated yet and isn't causing big problems. It aims to see if the drug can control the cancer with fewer side effects.
Boston, MassachusettsAges 18 years+
Lymphoma trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting lymphoma studies listed above.
- Dana-Farber Cancer Institute · 13 studies
- Beth Israel Deaconess Medical Center · 6 studies
- Mass General Brigham · 2 studies
- Massachusetts General Hospital · 2 studies
- Beth Israel Deaconess Medical Center (Data Collection Only)
- Brigham and Women's Hospital
- Call for Information (Investigational Site 0026)
- Dana Farber Cancer Institute (Data Collection and Specimen Analysis)
What taking part in a lymphoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Lymphoma trials in other states
Common questions
- Are there lymphoma clinical trials in Massachusetts?
- Yes. We're currently tracking 105 recruiting lymphoma studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lymphoma study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lymphoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lymphoma studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.